> Switzerland's Serono has filed a supplemental BLA for a new formulation of its MS drug Rebif. According to Phase III data, the new formulation is more easily tolerated by patients. Report [1]
> Achillion Pharmaceuticals has filed for a $75 million IPO. Report [2]
> Germany's Ingenium has raised €9.2 million in its fourth round of venture capital. Release [3]
> Unhappy Chiron shareholders were won over by Novartis' newly sweetened bid offer, paving the way for a merger. Report [4]
> The FDA has granted a priority review for Avanir Pharmaceuticals' Neurodex, a drug for under-treated emotional disorder. Report [5]
> The FDA has granted priority review for Remicade as a treatment for pediatric Crohn's disease. Report [6]
> Chutes & Ladders: SIGA Technologies' CEO Kasten Bernard has resigned. Report [7]
> Canada's Bioniche Life Sciences announced that the FDA has given its approval for a second Phase III trial of an experimental bladder cancer therapy. Article [8]
> ArQule is reporting positive Phase I data for ARQ501, its lead cancer therapy. Release [9]
> Halozyme Therapeutics says that preclinical and Phase I data for Chemophase supported the safety profile of the enzyme-chemo combination for bladder cancer. Release [10]
> Biosite and Oxford Genome Sciences have announced a collaboration to evaluate protein-based disease markers for colorectal cancer. Release [11]
> In a preclinical data presentation Antisoma said that data showed that a combination of its AS1404 and Avastin performed markedly better than Avastin alone in inhibiting the growth of human colon and lung tumour xenografts. Release [12]
And Finally... California plays a leading role in the spread of influenza, and researchers are struggling to find out why. Article [13]
Links:
[1] http://www.forbes.com/markets/feeds/afx/2006/04/04/afx2644324.html
[2] http://seattlepi.nwsource.com/business/1310AP_Achillion_IPO.html
[3] http://biz.yahoo.com/prnews/060404/netu008.html?.v=54
[4] http://www.sfgate.com/cgi-bin/article.cgi?file=/chronicle/archive/2006/04/04/BUGQRI2OAG1.DTL&type=business
[5] http://www.chron.com/disp/story.mpl/ap/fn/3769590.html
[6] http://www.businessweek.com/ap/financialnews/D8GP6RIG6.htm?campaign_id=apn_home_down&chan=db
[7] http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/210903/
[8] http://www.theglobeandmail.com/servlet/story/LAC.20060404.RBIONICHE04/TPStory/Business
[9] http://www.pharmalive.com/News/index.cfm?articleid=328482&categoryid=40
[10] http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-04-2006/0004332989&EDATE=
[11] http://biz.yahoo.com/prnews/060404/latu022.html?.v=51
[12] http://www.marketwire.com/mw/release_html_b1?release_id=120862
[13] http://www.nytimes.com/2006/04/04/health/04patt.html?_r=1&oref=slogin